Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Regenerative Medicine International's EBIT per Share for the
six
months ended in Dec. 2025 was $0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
During the past 12 months, the average EBIT per Share Growth Rate of China Regenerative Medicine International was -108.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of China Regenerative Medicine International was 55.90% per year. The lowest was -36.00% per year. And the median was -8.30% per year.
CNRMF's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
China Regenerative Medicine International (OTCPK:CNRMF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
China Regenerative Medicine International EBIT per Share Related Terms
China Regenerative Medicine International EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International EBIT per Share Chart
China Regenerative Medicine International Annual Data
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International (CNRMF) has a EBIT per Share of $0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on China Regenerative Medicine International and its competitors. According to the industry distribution chart, China Regenerative Medicine International ranks #999999 out of 1171 companies in the Biotechnology industry.
Is China Regenerative Medicine International's EBIT per Share too high?
China Regenerative Medicine International's current EBIT per Share is $0.01. The Biotechnology industry median EBIT per Share is 15.40. China Regenerative Medicine International's value of $0.01 is 99.9% below this industry median. Based on the distribution chart, China Regenerative Medicine International ranks #999999 out of 1171 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, China Regenerative Medicine International has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, China Regenerative Medicine International ranks #999999 out of 1171 companies for EBIT per Share. This places China Regenerative Medicine International in the lower half of its industry. The industry median EBIT per Share is 15.40. China Regenerative Medicine International's value of $0.01 is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,171 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Regenerative Medicine International's current EBIT per Share of $0.01 is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on China Regenerative Medicine International and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Regenerative Medicine International's current EBIT per Share is $0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
China Regenerative Medicine International (CNRMF) has a current EBIT per Share of $0.01. The stock's GF Value™ is $0.09, compared to a current price of $0.04 — trading 61.1% below its estimated fair value. The current EBIT per Share is $0.01 and 99.9% below the Biotechnology industry median of 15.40. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For China Regenerative Medicine International (CNRMF), the current EBIT per Share is $0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Regenerative Medicine International (CNRMF) Overvalued in 2026?
Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued.
The current stock price of $0.04 is trading 61.1% below its estimated GF Value™ of $0.09.
Key valuation signals for CNRMF:
EBIT per Share: $0.01
GF Value™: $0.09 vs. price of $0.04 (61.1% below fair value)
Industry Position: 99.9% below the Biotechnology median (#999999 of 1171)
No single metric tells the full story. See the CNRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score
Get the complete analysis for CNRMF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNRMF has been successfully added to your 
